Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EAU 2025 | Assessing the availability of theranostics in low & middle-income countries

Mike Sathekge • 17 Mar 2025
EAU 2025
Genitourinary Cancer

Mike Sathekge, MBChB, University of Pretoria, Pretoria, South Africa, comments on the accessibility of the latest theranostics, which are currently limited to the affluent, but emphasizes the need to make them affordable and accessible to all. The current approval and trial landscape disproportionately benefits high-income countries, excluding low and middle-income countries from participating in these technologies. This interview took place at the 2025 European Association of Urology (EAU) Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Mike Sathekge

Strategies to enhance the precision of PSMA theranostics
3:20
Strategies to enhance the precision of PSMA theranostics
Mike Sathekge • 17 Mar 2025
How can we make theranostics more accessible to everyone?
3:14
How can we make theranostics more accessible to everyone?
Mike Sathekge • 17 Mar 2025

Related Videos

Current and emerging systemic strategies in biochemically relapsed prostate cancer
2:45
Current and emerging systemic strategies in biochemically relapsed prostate cancer
Ashwin Sachdeva • 16 May 2026
How has SABR improved radiotherapy practice in kidney cancer?
1:06
How has SABR improved radiotherapy practice in kidney cancer?
Shankar Siva • 16 May 2026
Which patients with kidney cancer may benefit from SABR treatment?
1:58
Which patients with kidney cancer may benefit from SABR treatment?
Shankar Siva • 16 May 2026
Management of brain metastasis in patients with poor-risk testicular cancer
1:03
Management of brain metastasis in patients with poor-risk testicular cancer
Darren Feldman • 30 May 2026

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals